BACKGROUND: Treatment of necrotizing soft tissue infections (NSTIs) includes prompt surgical debridement and antibiotics, but despite standard care, the morbidity and mortality remain high. Since therapeutic plasma exchange (TPE) has been considered for treatment of severe sepsis, this study evaluates the efficacy of TPE for patients with NSTI.
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BACKGROUND: Treatment of necrotizing soft tissue infections (NSTIs) includes prompt surgical debridement and antibiotics, but despite standard care, the morbidity and mortality remain high. Since therapeutic plasma exchange (TPE) has been considered for treatment of severe sepsis, this study evaluates the efficacy of TPE for patients with NSTI.
STUDY DESIGN AND METHODS:
This is a retrospective study of patients with diagnosis of NSTI who received treatment with and without TPE over an 11-year period. The primary outcome was in-hospital mortality.
RESULTS:
Fifty-two patients with NSTI treated with TPE (TPE group) and 125 patients with NSTI not treated with TPE (non-TPE group) were assessed. Nineteen (36.5%) patients died in the TPE group, and 35 (28%) patients died in the non-TPE group. Within the TPE group, there was significant improvement in white blood cell (WBC) count and sodium levels 7 days after TPE treatment, but no improvement in creatinine. Inverse probability weighting based on propensity scores was used to compare survival in the TPE and non-TPE groups and demonstrated that TPE was associated with an increased odds of death (odds ratio, 2.8). A second analysis matched for six variables yielded 31 pairs and demonstrated no significant difference in mortality or length of stay.
CONCLUSIONS: This study describes the largest series of patients with NSTIs treated with TPE and showed no evidence of clinical benefit. Further carefully designed studies with meaningful clinical endpoints would prove useful in assessing reproducibility and determining if there is a role for TPE in other forms of severe sepsis. N ecrotizing soft tissue infections (NSTIs) are a heterogeneous group of infections with high morbidity and mortality. NSTIs lead to tissue destruction in the deep subcutaneous, fascial, and/or muscle compartments with systemic sepsis. They are often polymicrobial involving mixed aerobic-anaerobic bacteria, but may also be monomicrobial. Organisms found in NSTI include b-hemolytic streptococcus, methicillin-resistant Staphylococcus aureus, Enterococcus species, Clostridium species, Gram-negative bacilli, and fungi among others. 1, 2 Studies have shown significant variation in the epidemiology and microbiology of NSTIs between hospitals and between geographic regions.
hyperbaric oxygen therapy, and intravenous immunoglobulin G (IVIG) has been reported in severe NSTIs. 5 The literature on the use of TPE for patients with NSTIs is limited to two case reports. 6, 7 However, there are case series and clinical trials for the use of TPE in patients with severe sepsis with multiorgan failure. [8] [9] [10] [11] In severe sepsis, TPE is proposed to improve organ function and mortality by removing inflammatory mediators, fibrinolytic pathway inhibitors, and thrombogenic high-molecular-weight von Willebrand factor, while replacing anticoagulant proteins and ADAMTS13. The most recent guidelines from the American Society for Apheresis note that the limited available outcome data is insufficient to establish the optimum role of TPE in severe sepsis. 12 This case series reports the experience of a large academic medical center with the performance of TPE in NSTI cases over an 11-year period. The primary aim of this study was to assess whether TPE in NSTI was associated with any difference in in-hospital mortality compared to patients with NSTI and comparable illness severity who did not receive TPE.
PATIENTS AND METHODS

Data collection
The study was approved by the University of Washington Institutional Review Board. We performed a retrospective chart review of patients with NSTIs from January 2003 to January 2014. Only adult patients older than age 18 were included. Patients with NSTIs who underwent TPE were identified in an apheresis database. To obtain a non-TPE control group, a query of the medical center's electronic clinical database was made for patients from January 2003 to January 2014 to identify patients with International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes for gas gangrene (040.0), necrotizing fasciitis (728.86), and Fournier gangrene for males (608.83) plus either SIRS 995.9, shock 785.5, renal failure 584.5, 584.9, and/or coagulation defects 286.9, 286.7, 286.6. Next, Current Procedural Terminology codes for therapeutic apheresis procedures 36514, 36515, and 36516 were used to exclude patients who received TPE from the control group. Two surgeons (EB and HLE) adjudicated the NSTI diagnosis of potential control group patients based on review of operative reports. Records for patients included in the TPE and non-TPE groups were reviewed and the following data points were collected: admission and discharge date and time, age at admission, sex, race, inpatient mortality (yes/no), transfer from outside hospital (yes/no), microbial culture results, primary location of infection, laboratory data (sodium, creatinine, white blood cell [WBC] count, and hematocrit [Hct]), ventilator dependence, vasopressor and/or inotrope use in the first 24 hours of admission, amputation (yes/no), number of surgical debridements, and IVIG administration. For those patients who received TPE, procedure characteristics and adverse events associated with TPE were recorded.
TPE
TPE was performed based on physician discretion in a subset of patients with a diagnosis of severe NSTI. NSTI was considered severe in the presence of WBC counts greater than 30 3 10 9 /L, creatinine greater than 2 mg/dL, acute respiratory failure, or shock with dependence on inotropes and/or vasopressors. 6 The treatment plan included one TPE procedure using a 1.3-plasma-volume exchange. Additional treatments were performed at the discretion of the attending physician. All TPE procedures were performed using an apheresis system (COBE Spectra, Terumo BCT). All patients underwent TPE through a central line or received 100% replacement fluid with albumin or a combination of albumin and plasma depending on the international normalized ratio level and proximity to surgical debridement. ACD was used as the anticoagulant, and calcium gluconate was routinely administered during all TPE procedures.
Statistical analysis
Summary statistics of patient characteristics are presented as the median with lower and upper quartiles for continuous variables or number and percentage for categorical variables. Statistical comparisons were performed with computer software (R-3.2.2 for Windows, https://cran.r-project.org/bin/windows/base/old/3.2.2/) using the Fisher's exact test for categorical variables and the Mann-Whitney Wilcoxon test for continuous variables. Inverse probability weighting based on propensity scores was used to compute the causal influence of TPE on in-hospital mortality. First, propensity scores for the probability of receiving TPE were computed using a logistic regression model including a scale parameter for overdispersion and computer software (SAS/STAT, Version 9.1, SAS Institute). Covariates initially included in this model were ventilator dependence within the first 24 hours after admission, vasopressor and/or inotrope use within first 24 hours of admission, WBC count greater than 30 3 10 9 /L within first 24 hours of admission, high creatinine of more than 2 mg/dL within first 24 hours of admission, transfer from an outside facility, admission after 2008, IVIG administration, number of surgical debridements, whether amputation occurred, positive wound culture, presence of b-hemolytic streptococcal infection, presence of clostridial infection, whether the primary site of infection was an extremity, ethnicity, sex, and age. As previously described, such generous inclusion of covariates in the propensity score model is preferred. 13, 14 Backward elimination was performed to arrive at a final, parsimonious multivariable model of TPE. Secondarily, inverse probability weighting of the propensity score, which has been determined to be unbiased and robust to model misspecification, was used in the risk model for death. 13 The weights used are
where z i is the indicator for TPE treatment and e i is the propensity score (i.e., the modeled probability of receiving TPE). In this second model, we use in-hospital mortality as the outcome; otherwise we initially include all the same predictors, but also include TPE exposure and the weighting described from the model above. Again, backward elimination was performed to arrive at a final model.
RESULTS
Patient cohorts
Fifty-two patients with diagnosis of NSTI received TPE treatment from January 2003 to January 2014. The electronic query using ICD-9 codes found a potential cohort of 329 control group patients. After exclusion parameters were applied, a control group of 274 qualifying patients was identified, of which 125 patients were randomly selected and had full chart review and data collection for the study.
Analysis of patient characteristics showed significant differences in many variables ( Table 1 ). The TPE group was found to have significantly younger patients with higher median WBC count; increased number of surgical debridements; and an increased proportion of patients with transfer from an outside hospital, Clostridium spp. infection, ventilator and vasopressor/inotrope support within the first 24 hours of admission, extremity as the primary site of infection, and IVIG administration. The non-TPE group had higher median creatinine levels and a higher proportion of patients with b-hemolytic streptococcal disease and positive wound cultures.
Plasma exchange
Of the 52 patients treated with TPE, 35 (67.3%) received only one treatment, 11 (21.1%) received two, five (9.6%) received three, and only one patient received four treatments. Among the 17 patients receiving a second TPE procedure, nine were performed less than 1 day after the first (range, 0.5-8.86 days; median, 0.89 days; mean, 1.79 days). There was no difference in mortality between patients receiving one versus multiple procedures (37% vs. 35%, p 5 1.0). The majority of patients (92%) received a combination of plasma and albumin for replacement fluid. Adverse events attributed to TPE treatment included one patient having a mild allergic or febrile nonhemolytic 
* Categorical variables reported as number (%). Continuous variables reported as median (interquartile range). † In first 24 hours of admission.
transfusion reaction. Other reported adverse events deemed not to be associated with TPE but associated with the underlying medical condition, included six patients with hypotension, one patient death, and one patient transitioned to comfort care after severe decrease in blood pressure during TPE. The mean time to apheresis in the TPE group was 29.4 hours and did not vary significantly between survivors and nonsurvivors (28.3 and 31.5 hr, respectively; p 5 0.77). Laboratory values before TPE compared to Day 7 after the first TPE showed significant improvement in mean WBC count and sodium values; however, there was no significant difference in mean creatinine after TPE (Table 2 ). There was a significant decrease in Hct in patients before TPE and Days 1 and 7 after the first TPE.
Outcomes
Nineteen of 52 patients died in the TPE group (36.5%), and 35 of 125 patients (28%) died in the non-TPE group (p 5 0.29, Table 1 ). To account for differences in baseline characteristics between the TPE and non-TPE groups, a propensity score for likelihood of treatment with TPE was estimated using a logistic regression model. After backward elimination of covariates, the probability of receiving TPE remained significantly associated with ventilator dependence in the first 24 hours of admission, high admission WBC count, not having high creatinine, IVIG administration, and marginally, having infection in the extremities (Table 3) . In a final multivariate model for inhospital mortality including inverse probability weighting of the propensity score, TPE was associated with an increased odds of death (odds ratio [OR], 2.8; Table 4 ). Other covariates directly related to hospital death were older age, admission before 2008, having a WBC count of more than 30 3 10 9 /L, vasopressors or inotropes use, and fewer surgical debridements (Table 4 and Fig. 1 ). This last The first pair of boxes shows no weighting, and each additional pair of boxes to the right shows probabilities after adding the weight shown below. So the probabilities shown above "ventilation" include both "creatinine" and "ventilation", etc., and the probabilities at the far right were obtained after using all five predictors in computing weights.
measure may simply be an indicator of not having lived long enough to have additional surgeries. The final multivariable model includes black race because it is a confounder for the effect of TPE on mortality.
To support the conclusion of no clinical benefit of TPE in NSTI, a second statistical model matching TPE and non-TPE patients 1:1 for six variables including race, the time period of admission, WBC count of at least 30 3 10 9 /L, creatinine level of at least 2 mg/dL, ventilator dependence, and vasopressor or inotrope use in the first 24 hours of admission was performed and yielded 31 matched pairs. There were no significant differences in mortality or length of stay (supplemental data, available as supporting information in the online version of this paper).
DISCUSSION
This study represents the first and largest case series reporting the use of TPE for patients with the diagnosis of NSTI. 6, 7 After accounting for differences between the TPE and non-TPE groups using two different statistical models, we found no evidence of benefit from the use of TPE in NSTI. Randomized controlled trials (RCTs) for therapeutic apheresis in other cases of sepsis with multiorgan failure have also shown variable levels of response to TPE. 8, 9, 11 Busund and colleagues 9 completed the largest prospective RCT for TPE in sepsis (n 5 106) and found a significant improvement in 28-day all-cause mortality in the TPE group compared to the control group (33.3% vs. 53.8%, p 5 0.05). However, after correcting for differences in variables between the two groups such as age and site of infection, there was no longer a significant difference (p 5 0.07). The greatest survival advantage with TPE has been reported in thrombocytopenia-associated multiorgan failure in children. 10, 15 Two studies-one small prospective RCT in the United States (n 5 10) and another retrospective cohort analysis in Turkey (n 5 42)-have shown significantly higher 28-day survival in pediatric patients receiving plasma exchange compared to standard therapy. 10, 15 Yet, conflicting results have also been reported for pediatric patients. A meta-analysis of the four adult and pediatric RCTs on TPE in sepsis did not show an association with TPE and overall mortality, but subgroup analysis did suggest reduced mortality with TPE in adults but not pediatric patients. 16 The major limitations of our study are its retrospective nature and the lack of standardized use of TPE. Some surgeons were more apt to utilize TPE than others. Also, in many cases TPE was performed as the last resource before patient death. The NSTI patients receiving TPE in our study differed from the non-TPE group in numerous variables including a higher proportion of patients with respiratory and cardiovascular failure, extremity as the primary site of infection, IVIG use, and Clostridium spp. infection compared to the non-TPE group. A propensity scoreweighted analysis was employed to minimize some clinical disparities, but the covariates used in the model were indicators of disease severity at time of admission and may not accurately reflect the patient's condition when TPE was performed. There may also be other measures such as physician preference and patient risk factors that influence TPE use, but were not included in our model. For example, a previous study showed that a history of IV drug use and increased WBC count are associated with Clostridium spp. infection and poorer outcomes. 1 This information may have biased some clinicians to treat patients presenting with IV drug use and increased WBC count with more aggressive therapies. Other limitations of our study and many other studies evaluating the role of TPE in sepsis are the small number of high-acuity patients receiving a variety of treatment modalities, heterogeneity of disease, and lack of meaningful patient-centered outcomes beyond all-cause mortality. In an ideal study, measures of cardiovascular and respiratory status, kidney function, and WBC count could be used as additional outcomes. Also, all-cause inpatient mortality is not the ideal measure of treatment efficacy in sepsis, and novel clinical composite endpoints could be considered in future studies. 17, 18 Finally, our study lacks measurement of biomarkers that may have been removed or replaced by plasma exchange. Mortality in sepsis and NSTI has decreased over the past two decades. [19] [20] [21] Our study also notes decreased odds of in-hospital mortality as well as decreased utilization of TPE in patients admitted for NSTI after 2008. The apparent decrease in mortality is likely due to earlier recognition and treatment of sepsis and NSTI as well as improved intensive care unit care processes especially for resuscitation and mechanical ventilation. Another contributing or confounding factor though may be a concurrent increase in discharge to skilled nursing facilities. 22 The considerable decrease in use of TPE in NSTI patients admitted after 2008 may be attributable to physician preferences and availability of other treatments. Therapies for NSTI under active study include IVIG (NCT02111161; ClinicalTrials.gov) and a new drug named AB103 in Phase III clinical trials (NCT02111161, NCT02469857; ClinicalTrials.gov). 23 As these and other therapies become more widely accepted, we expect to continue to see a decline in the use of TPE in NSTI. The use of TPE in NSTI is controversial. Accumulated evidence has shown that therapeutic apheresis is most beneficial when a known substance with documented pathogenicity is meaningfully depleted. 24, 25 In the case of NSTI, there is no known substance in the vascular space being removed or any missing substance to replete. This study shows that there is no clinical benefit of TPE in patients with severe NSTI, but as with any other retrospective study the results should be interpreted within the context of its known and unknown limitations. While there may be unmeasured confounding variables remaining, the propensity scoring method used accounts for the influence of all measured cofactors associated with TPE and death. A carefully designed independent study with meaningful clinical endpoints and biomarker measurements would prove useful to confirm these observations.
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Additional Supporting Information may be found in the online version of this article at the publisher's website. /L, creatinine 2mg/dL, use of ventilator in the first 24 hours of admission, use of vasopressors or inotropes in the first 24 hours of admission, the time period of admission before or after 2008, and race. Table S2 . Summary of outcomes in NSTI patients with and without TPE after matched analysis. Mortality is reported as number (percent), and length of stay data is reported as median (interquartile range). Evaluation of inpatient mortality and length of stay in the matched cohorts demonstrate no statistically significant differences. Further analysis also showed no significant difference comparing length of stay in survivor and non-survivor subgroups.
